Passive immunization is provided in the following cases: If people can not synthesize antibodies When people of a disease are exposed, against which they have no immunity, or is likely to cause complications when people suffer from a disease and the effects of the toxin must be weakened for immunoglobulins and antitoxins that are available in the US, see table: available in the US immunoglobulins and antitoxins *. Available in the US immunoglobulins and antitoxins * immunobiological substances type indications botulinum antitoxin specific horse antibody treatment of botulism botulinum antitoxin (BIG) specific human antibody treatment of botulism in infants cytomegalovirus immunoglobulin IV (CMV-IGIV) specific human antibodies Prophylaxis in patients with hematopoietic stem cells and kidney diphtheria antitoxin specific horse antibody for the treatment of respiratory diphtheria hepatitis B immunoglobulin (HBIG) specific human antibodies Postexpositionelle hepatitis B prophylaxis immunoglobulin (Ig): Pooled human antibodies pre-exposure and post-exposure Hepatitis A prophylaxis, postexposure measles prophylaxis , immunoglobulin deficiency, R stuffs during the first trimester of pregnancy, varicella (if varicella-zoster immune globulin is unavailable) immunoglobulin, intravenous (IVIG) Pooled human antibodies prophylaxis and treatment (of serious bacterial and viral infections eg. B. HIV-infection in children), primary immunodeficiency diseases, autoimmune thrombocytopenia, chronic lymphocytic B-cell leukemia, Kawasaki’s disease, autoimmune diseases (e.g., B., myasthenia gravis, Guillain-Barre syndrome, polymyositis / dermatomyositis) prophylaxis against graft-versus-host disease immunoglobulin sc (SCIG): Pooled human antibody treatment of primary Immundeffekten rabies immunoglobulin (HRIG) specific human antibodies treatment of rabies postexpositionell in people who have been immunized previously with rabies vaccine (Rabies (rabies)) Respiratory syncytial virus murine monoclonal antibody ( RSV mAb) mouse monoclonal antibody (palivizumab) prevention of RSV in high-risk infants (infection with respiratory syncytial virus (RSV) and human metapneumovirus: prevention) Human immunoglobulin (Ig): specific human antibody treatment of tetanus post-exposure prophylaxis in individuals who were not adequately immunized with tetanus toxoid vaccinia immunoglobulin (VIG): Specific human antibody treatment of eczema vaccinatum, vaccinia necrosum and ocular vaccinia varicella zoster immunoglobulin (VariZIG) specific human antibodies post-exposure prophylaxis in individuals who no evidence of immunity, an increased risk of severe varicella and contraindications for varicella Impfsto ff have (Passive immunization: Human immunoglobulin (Ig)) * immunoglobulin preparations and antitoxins are i.m. administered, unless otherwise indicated. HRIG is administered to wounds around and i.m. Of the general recommendations for immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 43: 1, January 28, 1994. Updated by the Center for Biologics Evaluation and Research of the US Food and Drug Administration in 2008. Human immunoglobulin (Ig) Ig is a concentrated antibody solution obtained from the plasma of normal blood donors becomes. It consists mainly of IgG, although trace amounts of IgA, IgM and other serum proteins may be present. Ig can rarely transmitted viruses (eg., Hepatitis B or C, HIV) contain and is stable for months when stored at 4 ° C. Ig is i.m. administered. Since maximum serum antibody levels until at least 48 hours after i.m. Application can be achieved, Ig must be administered as soon as possible after exposure. The half-life of Ig in circulation is about 3 weeks. IG can be used for prophylaxis in hepatitis A measles immunoglobulin deficiency varicella (in immunocompromised patients when varicella-zoster IG is not available) exposure to rubella in the first trimester of pregnancy Ig gives only temporary protection, the level of antibodies against specific pathogens can vary by a factor of 10 depending on the preparation. The gift is painful, and anaphylaxis may occur. IIA immunoglobulin (IVIG) has been developed to administer higher doses and repeated human immunoglobulin. IVIg is particularly in the following used to treat or prevent serious bacterial and viral infections, autoimmune diseases and immunodeficiency diseases: Kawasaki syndrome HIV infection in children Chronic lymphocytic B-cell leukemia primary immunodeficiencies Immune orbeugung of graft-vs-host disease Side effects are rare, fever, chills, headache, weakness, nausea, vomiting, hypersensitivity, anaphylactic reactions, cough and overhydration but may occur. Subcutaneous immunoglobulin (SCIG) is made from pooled human plasma; SCIg is intended for home use in patients with primary immunodeficiency. Reactions at the injection site are common, but systemic side effects (eg., Fever, chills) are much less common than with IVIg. Hyperimmunoglobulin hyperimmune globulin is prepared from the plasma of individuals with high levels of antibodies against a specific pathogen or an antigen. It is obtained from people who have gone through natural infection or artificially immunized donors. Hyperimmunoglobulins available for hepatitis B, infantile botulism, rabies, tetanus, cytomegalovirus, smallpox and varicella zoster. The gift is painful, and anaphylaxis may occur. Monoclonal antibodies specific monoclonal antibodies that are active against infectious agents are of great theoretical interest and a number of them is currently under investigation. However, only one product, palivizumab, is currently available; It is active against RSV and is used for the prevention of RSV infection in certain high-risk children (infections with respiratory syncytial virus (RSV) and human metapneumovirus: Prevention).